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Abstract
Introduction The aim of this study was to describe the change
in serum procalcitonin levels during treatment for community-
acquired acute bacterial meningitis.
Methods Out of 50 consecutive patients presenting with
bacterial meningitis and infection at no other site, and who had
received no prior antibiotic treatment, 48 had a serum
procalcitonin level above 0.5 ng/ml on admission and were
enrolled in the study.
Results The mean age of the patients was 55 years, and mean
Glasgow Coma Scale score on admission was 13. The time
from symptom onset to admission was less than 24 hours in
40% of the patients, 24–48 hours in 20%, and more than 48
hours in 40%. The median (interquartile) interval between
admission and initial antibiotic treatment was 160 min (60–280
min). Bacterial infection was documented in 45 patients.
Causative agents included Streptococcus pneumoniae (n =
21), Neisseria meningitidis (n = 9), Listeria monocytogenes (n
= 6), other streptococci (n = 5), Haemophilus influenzae (n =
2) and other bacteria (n = 2). The initial antibiotic treatment was
effective in all patients. A lumbar puncture performed 48–72
hours after admission in 34 patients showed sterilization of
cerebrospinal fluid. Median (interquartile) serum procalcitonin
levels on admission and at day 2 were 4.5 (2.8–10.8) mg/ml and
2 (0.9–5.0) mg/ml, respectively (P < 0.0001). The
corresponding values for C-reactive protein were 120 (21–241)
mg/ml and 156 (121–240) mg/ml, respectively. Five patients
(10%) died from noninfectious causes during their
hospitalization.
Conclusions Serum procalcitonin levels decrease rapidly with
appropriate antibiotic treatment, diminishing the value of lumbar
puncture performed 48–72 hours after admission to assess
treatment efficacy.
Introduction
Community-acquired acute bacterial meningitis (ABM) in
adults remains a serious disease, with mortality rates of 10–
25% [1,2]. In the context of emergency presentation, the man-
agement decisions to be made once the diagnosis has been
established concern the initial antibiotic treatment [2], adju-
vant therapies [3,4] and treatment of organ failure [5].
Antibiotic treatment must be started rapidly [6] and must be
appropriate, particularly when risk factors are present [7,8],
although the timing of antibiotic therapy initiation does not
appear to be an independent prognostic factor [9-11]. The
choice of antibiotic treatment, addressed in numerous national
[12] and international [2,13-15] recommendations, is based
on aetiological indices, risk factors, the results of direct exam-
inations and knowledge of bacterial ecology.
The efficacy of this initial antibiotic therapy is assessed on the
basis of clinical course of the disease and analysis of cerebro-
spinal fluid (CSF) samples obtained 48–72 hours after theR344
ABM = acute bacterial meningitis; CRP = C-reactive protein; CSF = cerebrospinal fluid; MIC = minimum inhibitory concentration; PCT = 
procalcitonin.
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R345start of treatment, when available, although cytochemical CSF
parameters appear to be little modified by appropriate antibi-
otic treatment [16]. A marker that can demonstrate efficacy at
an earlier stage would be extremely useful.
In 1993 Assicot and coworkers [17] demonstrated the value
of serum procalcitonin (PCT) as a marker of infectious states
of bacterial orgin in neonates and infants, as well as the rapid
decrease in its concentration with appropriate antibiotic treat-
ment. The aim of the present study was to describe the varia-




This was a prospective study and included patients admitted
to the adult emergency department with community-acquired
bacterial meningitis between January 1997 and October
2003. The demographic and clinical characteristics of the
patients were recorded on admission.
Bacterial meningitis was diagnosed if pathogenic bacteria
were detected in the CSF. In the absence of documented evi-
dence of bacterial infection, this diagnosis was made if the pol-
ymorphonuclear leucocyte count in the CSF exceeded 250/
mm3 and the CSF/serum glucose ratio was below 0.4, with a
compatible clinical state, necessitating antibiotic treatment for
7 days or longer. Patients presenting with a further site of
infection in addition to meningitis on admission, having
received prior antibiotic treatment for more than 2 consecutive
days or showing a serum PCT level of 0.5 mg/ml or less, were
excluded from the study.
Laboratory tests
Blood samples for C-reactive protein (CRP), PCT, fibrinogen,
lactate and creatinine assays, and complete blood count were
taken on admission, then once daily during the first week. Lum-
bar puncture (for total and polymorphonuclear leucocyte
count and assay of proteins, lactate and glucose) and bacteri-
ological sampling (blood cultures) were performed before
starting the initial antibiotic treatment. These tests could be
repeated between 48 and 72 hours later at the discretion of
the clinician.
The interval between admission and administration of the first
dose of antibiotic was recorded. Bacterial sensitivity to antibi-
otics was routinely tested by determining the minimum inhibi-
tory concentrations (MICs) of penicillin, amoxicillin, cefotaxime
and ceftriaxone. With regard to penicillin, bacteria were con-
sidered to be sensitive if the MIC was 0.1 mg/l or less, of inter-
mediate resistance if the MIC was above 0.1 mg/l but no
greater than 1 mg/l, and highly resistant if the MIC was above
1 mg/l. For amoxicillin, cefotaxime and ceftriaxone, bacteria
were considered to be sensitive if the MIC was 0.5 mg/l or
less, of intermediate resistance if the MIC was above 0.5 mg/
l but no greater than 2 mg/l, and highly resistant if the MIC was
greater than 2 mg/l.
Serum PCT levels were determined using an immunolumino-
metric assay (Brahms Diagnostica, Berlin, Germany) with a
limit of detection of 0.07 mg/ml.
Treatment and course of illness
The efficacy of initial antibiotic treatment was assessed on the
basis of in vitro bacterial sensitivity to antibiotics, bacteriolog-
ical analysis of CSF samples drawn 48–72 hours after treat-
ment initiation, and clinical course. The nature and duration of
antibiotic treatment, and any modifications to this, were
recorded. Mortality and sequelae were assessed at 30 days.
Statistical analysis
Results are expressed as mean ± standard deviation or as
median (interquartile range). The box plots are presented with
the interquartile range. The values at day 0 (D0; admission)
and day 2 (D2) were compared using Wilcoxon's nonparamet-
ric test for repeated measurements for quantitative parameters
and the χ2 test for qualitative parameters, with the threshold of
significance set at P < 0.05.
Results
During the study period (82 months), 59 patients presenting
with ABM were admitted to the emergency department.
Eleven patients were excluded for the following reasons: anti-
biotic treatment before admission (n = 6), presence of another
site of infection (pneumopathy, n = 2; spontaneous bacterial
peritonitis, n = 1), and serum PCT concentration 0.5 mg/ml or
less on admission (one ABM due to pneumococci, one ABM
due to unidentified bacteria).
The clinical characteristics of the 48 patients are summarized
in Table 1. The mean interval between admission and lumbar
puncture was 90 ± 40 min and the mean time elapsing from
admission to injection of the first dose of antibiotic was 120 ±
70 min.
The microbiological results obtained are shown in Table 2.
Among the 21 pneumococcal infections documented, 13 iso-
lates (62%) were sensitive to penicillin, six (29%) were of
intermediate resistance and two (10%) were resistant. Among
the six strains with intermediate resistance to penicillin, four
were sensitive to amoxicillin or to ceftriaxone, and two exhib-
ited intermediate resistance. The two strains resistant to peni-
cillin exhibited intermediate resistance to amoxicillin or to
ceftriaxone. The initial antibiotic treatment comprised amoxicil-
lin (150–200 mg/kg per day), ceftriaxone (60–80 mg/kg per
day), or a combination of these. All of the pneumococcal
strains with reduced sensitivity to penicillin were at least
exposed to ceftriaxone during the initial treatment, with analy-
sis of CSF samples drawn between 48 and 72 hours after the
Available online http://ccforum.com/content/9/4/R344
R346start of treatment showing sterilization in all cases. Antibiotic
treatment was simplified eight times out of 21 on the basis of
the results of microbiological analysis of CSF samples.
All of the other bacteria identified were sensitive to amoxicillin,
with the initial antibiotic therapy being appropriate in all cases.
The treatment was simplified between 24 and 72 hours after
the start of treatment in six patients out of 24 on the basis of
the results of microbiological analysis of the CSF.
For the three patients with a CSF culture not showing any evi-
dence of bacteria, antibiotic treatment with amoxicillin and
ceftriaxone was started on admission and continued for 15–
20 days.
Table 1
Patient characteristics on admission
Characteristics Number of patients (n = 48)
Demographic characteristics
Age (years; mean ± SD) 55 ± 21
Patients >75 years (n [%]) 8 (17)
Male (n [%]) 21 (44)
Duration of symptoms (hours; n [%])
<12 hours 4 (8)
12–23 hours 15 (31)
24–48 hours 10 (21)
>48 hours 19 (40)
Clinial characteristics (n [%])
Fever (>38°) 43 (90)
Headache 29 (60)
Nuchal rigidity 35 (73)
Seizures 4 (8)
Purpura 5 (10)
Focal neurological deficit 5 (10)
Glasgow Coma Scale score (mean ± SD) 13 ± 2
Simplified Acute Physiology Score II (mean ± SD) 18 ± 10
SD, standard deviation.
Table 2
Bacteriology of CSF on admission
Organism CSF Gram stain (n = 48) Culture (n = 48)
Streptococcus pneumoniae (n [%]) 12 (25) 21 (44)
Neisseria meningitidis (n [%]) 6 (12) 9 (19)
Other streptococci (n [%]) 0 5 (10)
Listeria monocytogenes (n [%]) 0 6 (13)
Haemophilus influenzae (n [%]) 0 2 (4)
Escherichia coli (n [%]) 0 1 (2)
Staphylococcus aureus (n [%]) 0 1 (2)
Total (n [%]) 18 (38) 45 (94)
CSF, cerebrospinal fluid.
Critical Care    Vol 9 No 4    Viallon et al.
R347The changes in serum and CSF cytochemical parameters are
shown in Tables 3 and 4 and in Fig. 1. With regard to the CSF,
only the lactate concentration differed significantly between
D0 and D2. Sterilization of the CSF was noted in the 34
patients who underwent a second lumbar puncture. In the 14
patients who did not undergo a repeat lumbar puncture, the
duration of antibiotic treatment was 12–16 days, resulting in
cure in all cases, and the duration of hospital stay was
between 13 and 18 days. With respect to serum parameters,
the decrease in PCT level was the only significant difference
observed between D0 and D2.
Among the 48 patients, five patients (9%) died between 12
and 28 days after their admission to hospital. Only one of
these patients was younger than 75 years. All of these patients
underwent a second lumbar puncture during treatment, with
analysis of the resulting sample showing sterilization of the
CSF in all cases, which was confirmed by a third lumbar punc-
ture in three of the five patients. A serum PCT concentration
below 0.5 ng/ml was observed in all patients between 6 and 9
days after admission. The cause of death was multiple organ
failure (n = 1), cerebral thrombophlebitis (n = 1) and cerebral
oedema (n = 3). Four patients had neurological sequelae at 30
days.
Discussion
In the present study a significant and early decrease in serum
PCT concentration was associated with cure of meningitis. In
contrast, analysis of CSF showed a significant decrease only
in lactate concentration between 48 and 72 hours after the
first lumbar puncture.
The value of repeat lumbar puncture at 48 hours remains
debatable, and second-line antibiotic treatment is based
essentially on the MIC of various antibiotics for the bacteria
identified or on the clinical course [2,6,12,13,18]. Apart from
the microbiological data, the CSF parameters traditionally
described during ABM appear to be little modified by
appropriate antibiotic therapy within 48 hours. Blazer and
coworkers [16], studied the effect of antibiotic treatment on
the CSF parameters of 68 children presenting with ABM.
None of the cytochemical parameters studied (proteins, glu-
cose, total and polymorphonuclear leucocytes) exhibited a sig-
nificant decrease between the first lumbar puncture and a
second lumbar puncture performed 44–68 hours after the
start of antibiotic therapy, whereas two bacteria were still
detectable in the repeat CSF samples drawn. Similar findings
were reported by Bland and coworkers [19] concerning the
changes in these cytochemical parameters after 24–72 hours
of treatment for ABM in 15 children.
Different results were obtained in an animal study [20]. In five
sheep, treatment for an experimentally induced meningitis due
to Escherichia coli resulted in a rapid decrease in polymorpho-
nuclear leucocyte count in the CSF, which was associated
with an increase in glucose concentration and a decrease in
protein concentration. However, in that study antibiotic treat-
ment was administered intrathecally. In the present study there
Table 3
Cytochemical parameters of CSF and CSF/serum ratio on admission and after 2–3 days of treatment
Parameter Day 0 (admission; n = 48) Day 2 (2–3 days of treatment; n = 34)
Leucocyte count (cells/mm3) 757 (366–2730) 580 (309–2025)
Polymorphonuclear leucocyte count (cells/mm3) 605 (258–2482) 417 (254–1762)
Protein level (g/l) 4.2 (2–6.2) 3.9 (1.8–5)
Glucose CSF level (mmol/l) 2.4 (0.8–3.6) 2.5 (1.2–3)
CSF/serum glucose ratio 0.31 (0.1–0.48) 0.35 (0.17–0.5)
Lactate CSF level (mmol/l) 8.74 (5.5–13) 5* (3–9)
CSF/serum lactate ratio 3.22 (2.4–4.7) 2.73 (1.5–3.3)
Values are expressed as median (interquartile range). CSF, cerebrospinal fluid. *P < 0.001.
Table 4
Change in serum biological parameters from admission to day 4 of treatment
Parameter Day 0 Day 1 Day 2 Day 3 Day 4
Leucocyte (109/l) 14.2 (10–19) 14 (11.8–18) 13.5 (11–17) 10.5 (8.5–12) 10.2 (8–13)
Fibrinogen (g/l) 4.8 (4–6.4) 6.2 (5–7.5) 6.2 (5.6–8.2) 6.4 (5.8–8.4) 6.3 (5–8)
C-reactive protein (mg/l) 120 (48–241) 221 (141–299) 156 (121–240) 93 (67–170) 82 (43–130)
Procalcitonin ng/ml) 4.5 (2.8–10.8) 3.8 (1.5–10.7) 2* (0.9–5) 1.4 (0.4–3) 0.7 (0.4–1.3)
Values are expressed as median (interquartile range). *P < 0.0001 versus day 0.
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cyte count or protein concentration in the CSF after 48–72
hours of appropriate antibiotic treatment. The glucose concen-
tration measured in the CSF remained stable, but there was a
significant decrease in lactate concentration.
Although numerous articles have demonstrated the value of
assaying lactate during the course of ABM [19,21-27], few
data exist concerning the changes in this parameter during the
treatment of this disease. In 21 patients with ABM, Gontroni
and coworkers [23] showed a rapid decrease in lactate con-
centration in the CSF during the first 24 hours of treatment.
Gould [22], Bland [19] and Genton [21] and their groups
obtained similar results concerning the change in lactate con-
centration in CSF after 24–72 hours of treatment in 6, 15 and
25 patients with ABM, respectively. In the study reported by
Bland and coworkers [19], the mean lactate concentration in
the CSF was 75.1 ± 6.6 mg/100 ml at the time of the first lum-
bar puncture and 49.5 ± 5.7 mg/100 ml after 24–72 hours of
treatment.
With regard to the changes in serum parameters, the present
study revealed a rapid decrease in PCT concentration within
the first 24 hours of treatment, which was accompanied by an
increase in CRP, with the level of CRP diminishing only after
2–3 days.
In 1993, Assicot and coworkers [17] demonstrated that serum
PCT concentration was a marker of infectious states of bacte-
rial origin in children, exhibiting a rapid decrease following anti-
biotic treatment. Although several studies have demonstrated
the value of serum PCT concentration in the differential diag-
nosis of ABM and viral or aseptic meningitis [28-31], few data
are available concerning the change in serum PCT during
treatment for ABM. Schwartz and colleagues [31] reported a
reduction in median serum PCT concentration from 1.75 mg/
ml at baseline to 1.05 mg/ml after 48 hours of treatment in 11
patients with ABM. In three of these patients, the PCT concen-
tration remained unchanged, or increased, in conjunction with
an unfavourable clinical course. In the study reported by Gen-
drel and coworkers [28], conducted in eight children receiving
Figure 1
Evolution of CRP and PCT levels over 72 hours l l  v r 2 hours. Change in serum levels of C-reactive protein (CRP) and procalcitonin (PCT) from admission (day 0) 
to 72 hours after the start of treatment.
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within 24 hours of treatment in all but two cases.
Although appropriate antibiotic therapy appears to be corre-
lated with a rapid decrease in PCT levels, the absence of
patients receiving an inappropriate treatment in our series did
not allow us to determine the change in PCT levels under
these circumstances. What are the arguments in support of a
relationship between decrease in PCT levels and appropriate
antibiotic treatment? Smith and coworkers [32] investigated
the value of PCT in 43 patients presenting with melioidiosis of
various grades of severity. Among the 16 patients with a
severe infection, 13 exhibited a decrease in PCT levels from
the first day of treatment. In the three other patients an
increase in PCT levels was observed in relation to infectious
complications (pulmonary abscess, septic arthritis, splenic
abscess). In two patients the Pseudomonas pseudomallei
infection detected was resistant to the initial antibiotic therapy.
Although the change in serum levels of CRP has been shown
to be of value for tracking the course of a bacterial infection
during treatment [33,34], the characteristics of this protein are
such that its concentration reaches a maximum only after 24–
48 hours [35]; this is in contrast to PCT, which attains a peak
serum concentration more rapidly. After injection of endotoxin,
the peak serum concentration of PCT is reached within
approximately 8 hours [36].
Certain limitations of the present study should be mentioned.
This was a descriptive study of the variation in serum PCT con-
centrations over time in patients who had received appropriate
antibiotic treatment from the moment they were admitted to
hospital. We currently have no data on changes in serum PCT
levels occurring in patients who did not receive suitable treat-
ment. Two patients with bacterial meningitis were not included
in the study on the grounds that they presented with a serum
procalcitonin level below 0.5 ng/ml on admission. At present
there is no clear explanation for this finding. Several studies
have reported low levels of serum PCT during ABM
[30,31,37]. For the most part, this occurred in patients pre-
senting with bacterial meningitis caused by intracellular bacte-
ria or nosocomial infections [31,37].
Conclusion
The change in serum PCT level during treatment for commu-
nity-acquired ABM appears to be a valuable parameter for
evaluating the efficacy of antibiotic therapy. This hypothesis
needs confirmation, particularly in patients presenting with
bacterial meningitis that is not microbiologically documented.
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